Global Bacterial Conjunctivitis Drugs in Development, 2021 - Find Out the R&D Progress and MoA of CTI-005, IC-702, Mul-1867, SHP-640, and More

DUBLIN, Dec. 9, 2021 /PRNewswire/ -- The "Bacterial Conjunctivitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Companies Mentioned

• Cellics Therapeutics Inc.
• IACTA Pharmaceuticals Inc.
• Kurobe LLC
• Laboratorios Sophia SA de CV
• NTC srl
• Takeda Pharmaceutical Co. Ltd.
• TGV-Inhalonix Inc.

Report Highlights

This guide provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 4, 2 and 1 respectively.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the Guide

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

Introduction

Bacterial Conjunctivitis - Overview

• Bacterial Conjunctivitis - Therapeutics Development

Pipeline Overview

• Pipeline by Companies
• Products under Development by Companies

Bacterial Conjunctivitis - Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Bacterial Conjunctivitis - Companies Involved in Therapeutics Development

• Cellics Therapeutics Inc.
• IACTA Pharmaceuticals Inc.
• Kurobe LLC
• Laboratorios Sophia SA de CV
• NTC srl
• Takeda Pharmaceutical Co. Ltd.
• TGV-Inhalonix Inc.

Bacterial Conjunctivitis - Drug Profiles

• CTI-005 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• IC-702 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• ketorolac tromethamine + levofloxacin - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Mul-1867 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• pazufloxacin - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• SHP-640 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• vancomycin hydrochloride - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress

Bacterial Conjunctivitis - Dormant Projects

Bacterial Conjunctivitis - Product Development Milestones

Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/r/pui31l

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com